Blue Fin Group is proud to announce the promotion of Bruce Phelan to Partner, effective April 1, 2021.
Bruce has over 30 years of industry and consulting experience. He is a skilled and trusted advisor to clients, including Chief Commercial Officers and leaders of marketing, market access, field sales, patient services and trade & distribution departments.
Bruce has deep expertise in Cell and Gene Therapies (CGT) and is currently working on eight assets, over a dozen Orphan & Rare products and several more products in Oncology, Immunology and Neurology. Bruce was the lead consultant who helped define the market for Spinal Muscular Atrophy, the blueprint which now serves as the basis for how CGT products are commercialized.
In Bruce’s time at Blue Fin Group, he has proven his skills as a consultant and commercial leader. Clients appreciate his ability to dig deep into topics while remaining broad and connecting the disparate silos that challenge so many commercial teams in life sciences.
Bruce strives to make a difference in our industry, with our clients, and our internal teams. He works across the Top 20 pharmaceutical manufacturers and has a passion for assisting emerging pharmaceutical companies developing their initial commercialization plans.
We applaud Bruce on this achievement. His continued leadership will be invaluable in helping to fulfill Blue Fin Group’s vision of enabling science to come to market and ensuring that patients maintain affordable access to care, and the therapies required.